United States Patent 3,761,590: Silver Sulfadiazine Claims, Scope, Expiration, and Patent Landscape

U.S. Patent 3,761,590 covers the topical treatment of burns with silver sulfadiazine, including formulations in hydrophilic carriers and oil-in-water cream emulsions. It issued on September 25, 1973, and its patent term expired in 1990 under the pre-Uruguay Round patent term rule. The patent no longer creates a U.S. market-exclusion right. Current commercial protection for silver sulfadiazine depends on FDA approval requirements, trademarks, manufacturing know-how, and any later patents, not Patent 3,761,590 itself. [1]

What does U.S. Patent 3,761,590 cover?

The patent covers a method of treating burns by applying a therapeutically effective amount of silver sulfadiazine to the affected area. Claim 1 is the independent method claim from which the supplied claims depend. The patent is directed to therapeutic use and formulation context rather than to a new chemical composition of matter.

The core invention can be reduced to four elements:

A burn is being treated.
Silver sulfadiazine is the active agent.
The active agent is applied to the burn area.
The amount applied is therapeutically effective.

Claims 2 through 6 narrow that method by specifying the carrier, dosage concentration, and formulation components.

Claim	Principal limitation	Practical scope
1	Application of a therapeutically effective amount of silver sulfadiazine to a burn	Broad method claim
2	Silver sulfadiazine dispersed in a water-dispersible, hydrophilic carrier	Narrows claim 1 by carrier type
3	Silver sulfadiazine dispersed in a semi-soft or cream-like, water-dispersible or water-soluble oil-in-water emulsion	Covers cream-type topical products
4	Claim 2 carrier contains about 0.1% to about 10% silver sulfadiazine by weight	Adds concentration range
5	Claim 3 emulsion contains about 0.1% to about 10% silver sulfadiazine by weight	Covers defined cream concentration range
6	Claim 2 formulation with specified excipient classes and concentration ranges	Most compositionally specific supplied claim

How broad is claim 1 of Patent 3,761,590?

Claim 1 is materially broader than claims 2 through 6 because it does not depend on a particular cream base, excipient system, concentration range, or dosage form. A product or treatment method falling within the claim would need to use silver sulfadiazine to treat a burn, but the claim does not appear limited to a particular carrier.

Historically, this structure gave the patent several possible enforcement theories:

A topical cream containing silver sulfadiazine.
A hydrophilic gel or other water-dispersible vehicle.
A burn-treatment protocol using silver sulfadiazine at a therapeutically effective dose.
A formulation outside the specific excipient ranges of claim 6, provided it still satisfied claim 1 or another dependent claim.

The breadth of claim 1 would have made it the commercially important claim. Claims 2 through 6 functioned as fallback claims focused on formulation and concentration limitations.

The claim is a method-of-treatment claim, not a product-by-process claim. It does not claim silver sulfadiazine as a new chemical entity. It also does not claim every pharmaceutical use of silver sulfadiazine.

What formulations are protected by claims 2 through 6?

What does claim 2 protect?

Claim 2 requires silver sulfadiazine to be applied as a dispersion in a water-dispersible, hydrophilic carrier. The claim does not specify exact excipients or a numerical concentration.

Potentially relevant carriers include aqueous or water-compatible systems that disperse the active ingredient and can be removed or diluted with water. The claim language is broader than a conventional oil-in-water cream because it is not limited to a semi-soft or cream-like vehicle.

A formulation that uses a non-water-dispersible, substantially anhydrous, or otherwise incompatible carrier could avoid claim 2 while remaining exposed to claim 1 if used for burn treatment.

What does claim 3 protect?

Claim 3 is directed to a semi-soft or cream-like, water-dispersible or water-soluble oil-in-water emulsion carrier. It covers the product architecture associated with silver sulfadiazine burn cream.

The relevant limitations are cumulative:

The carrier must be semi-soft or cream-like.
It must be water-dispersible or water-soluble.
It must be an oil-in-water emulsion.
Silver sulfadiazine must be dispersed in that carrier.

A water-in-oil emulsion is not literally within the stated oil-in-water limitation, although infringement could depend on the actual formulation structure and the application of equivalents principles. A liquid solution, ointment, powder, spray, or dressing would not automatically satisfy claim 3.

What do claims 4 and 5 protect?

Claims 4 and 5 add a silver sulfadiazine concentration of about 0.1% to about 10% by weight.

The range is broad. A conventional 1% cream falls within it. The use of the term "about" creates a potential boundary issue around the endpoints, but it does not eliminate the central coverage of ordinary commercial concentrations.

Claim 4 applies the range to the hydrophilic carrier described in claim 2. Claim 5 applies the same range to the oil-in-water cream carrier described in claim 3.

What does claim 6 protect?

Claim 6 is the narrowest of the supplied claims. It requires the claim 2 carrier and specifies a formulation consisting essentially of the following components:

Component	Claimed range
Petrolatum	0% to 25%
Long-chain fatty alcohol, C16-C22	7% to 45%
Silver sulfadiazine	0.1% to 10%
Nonionic emulsifying agent	4% to 16%
Humectant selected from propylene glycol, sorbitol, or glycerin	7% to 40%
Emollient	0% to 15%
Water	Quantity sufficient to total 100%

The phrase "consists essentially of" is significant. It generally permits components that do not materially change the basic characteristics of the claimed formulation, while restricting additional ingredients that would materially alter those characteristics.

Claim 6 also contains open-ended range issues. A formulation can include zero petrolatum or zero emollient because those ranges begin at 0%. The required ingredients are the long-chain fatty alcohol, silver sulfadiazine, nonionic emulsifier, and one of the specified humectants, together with water as needed.

How does the claimed formulation compare with Silvadene cream?

Silvadene cream is a 1% silver sulfadiazine topical cream indicated for the prevention and treatment of wound sepsis in patients with second- and third-degree burns. FDA labeling identifies silver sulfadiazine as the active ingredient and describes the product as a cream for topical use. [2]

The commercial 1% concentration falls within claims 4, 5, and 6. Whether a specific Silvadene formulation satisfied every limitation of claim 6 would require a product composition record from the relevant period. The patent’s claim language alone does not establish that every marketed 1% cream had each listed excipient within the recited ranges.

The legal distinction is important:

A 1% silver sulfadiazine cream could fall within the broad therapeutic method claim.
It could fall within claim 5 if it used the required oil-in-water cream carrier.
It could fall within claim 6 only if its full excipient profile met the specified component and percentage limitations.
Patent 3,761,590 cannot presently block manufacture or sale because it has expired.

When did Patent 3,761,590 lose exclusivity?

Patent 3,761,590 issued on September 25, 1973. Under the patent term rules applicable to the patent, the term was generally 17 years from issuance. The resulting expiration date was September 25, 1990, absent an unusual adjustment or extension. The patent predates the modern 20-year-from-effective-filing-date regime created by the Uruguay Round Agreements Act. [1,3]

Event	Date
Patent issued	September 25, 1973
Applicable term framework	Generally 17 years from issue
Estimated statutory expiration	September 25, 1990
Current status	Expired
Current blocking effect	None

Patent term restoration under the Hatch-Waxman framework does not appear to create a current extension for this patent. Even if the underlying drug product received FDA approval after issuance, the relevant term period had already ended decades ago.

What is the Orange Book status of silver sulfadiazine?

Silver sulfadiazine is a small-molecule drug, and approved generic versions are regulated through the ANDA pathway rather than the biosimilar pathway. The FDA Orange Book identifies approved drug products and, where applicable, patent and exclusivity information associated with listed reference products. [4]

The key regulatory points are:

Silvadene is associated with silver sulfadiazine topical products.
A 1% cream is the principal commercial dosage form.
Generic applicants may rely on the reference product through the ANDA pathway.
An expired 1973 patent is not a current Orange Book barrier.
Patent 3,761,590 does not provide a current Paragraph IV target with remaining enforceable term.

Orange Book status must be distinguished from patent status. An FDA-listed product can remain commercially relevant after all pioneer patents expire. Conversely, a patent may be technically listed in an historical record without retaining enforceable term.

Are there Paragraph IV challenges or generic litigation tied to this patent?

Patent 3,761,590 is too old to support a current Paragraph IV challenge. A Paragraph IV certification contests the validity, enforceability, or infringement of a listed patent with unexpired term. An expired patent does not create a present litigation stay or launch bar.

The relevant generic pathway is an ANDA referencing an approved silver sulfadiazine product. Generic applicants may still face regulatory requirements concerning:

Active ingredient identity and strength.
Pharmaceutical equivalence.
Product quality and microbiological controls.
Demonstration of therapeutic equivalence where required.
Labeling and manufacturing compliance.

Those requirements are regulatory barriers, not rights arising from Patent 3,761,590.

No current patent settlement or active enforcement right can be attributed to this expired patent based on its present legal status. Historical licensing or litigation involving silver sulfadiazine products would require a separate case-specific record and would not revive the patent.

How strong is the patent estate for silver sulfadiazine?

The current U.S. patent estate associated specifically with Patent 3,761,590 has no blocking strength because the patent expired.

Historically, its strength had two dimensions:

The broad method claim potentially covered topical use of silver sulfadiazine for burns across multiple formulations.
The dependent claims supplied narrower positions directed to hydrophilic and oil-in-water cream carriers.

Its weaknesses would have included the following:

The active compound was already the defined therapeutic agent in the claims rather than a newly claimed chemical entity.
Formulation claims could be avoided through changes in carrier architecture or excipient concentrations.
Claim 6 required close matching of multiple percentage ranges.
The patent did not provide continuing protection for unrelated indications, delivery systems, or manufacturing processes.

Today, the relevant risk is commercial rather than patent-based. A competitor may need to overcome formulation development, FDA quality requirements, supply-chain controls, and brand recognition, but Patent 3,761,590 does not prevent market entry.

What manufacturing and formulation barriers remain?

Silver sulfadiazine products can face technical barriers even without live patent protection.

Active pharmaceutical ingredient

Manufacturers must control silver sulfadiazine identity, purity, particle characteristics, residual solvents, elemental impurities, and microbial quality. Silver-containing materials can create stability and compatibility issues with excipients and packaging.

Cream manufacturing

A 1% topical cream requires control of:

Particle dispersion.
Emulsion phase structure.
Uniformity of silver sulfadiazine throughout the batch.
Viscosity and spreadability.
Container compatibility.
Microbial limits and preservative performance.
Stability under intended storage conditions.

These factors can create development time and manufacturing cost, but they are not exclusive rights under Patent 3,761,590.

Later intellectual property

A competitor would need to assess later patents covering particular:

Formulation systems.
Particle-size distributions.
Packaging or dispensing systems.
Wound-dressing combinations.
Manufacturing processes.
New indications or combination therapies.

Those rights cannot be inferred from Patent 3,761,590 and require a separate family-level search.

How does silver sulfadiazine compare with competing burn treatments?

Silver sulfadiazine competes with modern wound-care products, topical antimicrobials, non-silver dressings, and systemic or procedural approaches. Its commercial position has been affected by concerns that routine use may delay wound healing in some settings and by the adoption of alternative dressings and outpatient treatment protocols.

The patent comparison is straightforward:

Product category	Main protection issue
Silver sulfadiazine cream	Expired composition and method patent; generic competition
Silver-impregnated dressings	Potentially newer formulation, device, and combination patents
Topical antibiotic ointments	Separate active-ingredient and formulation estates
Advanced wound dressings	Device patents, material patents, and proprietary manufacturing
Biologic wound products	Biologics regulation, exclusivity, and biosimilar or interchangeable-product issues

Silver sulfadiazine itself is not a biologic. Biosimilar risk is therefore not applicable to the active ingredient or to conventional silver sulfadiazine cream. The relevant competitors are generic small-molecule products and alternative wound-care technologies.

What is the geographic coverage of Patent 3,761,590?

Patent 3,761,590 is a United States patent. Its expiration eliminates U.S. enforcement rights, but the patent does not determine rights in Europe, Canada, Japan, China, or other jurisdictions.

Foreign protection would depend on separate national applications, grants, expiration dates, prosecution histories, and possible supplementary protection rights. The U.S. patent number cannot be used to infer foreign patent coverage.

Key Takeaways

Patent 3,761,590 covers burn treatment with silver sulfadiazine.
Claim 1 is the broad method claim; claims 2 through 6 narrow the carrier, emulsion type, concentration, and excipient profile.
Claims 4 and 5 cover silver sulfadiazine concentrations of about 0.1% to 10% by weight.
Claim 6 is a detailed formulation claim requiring specified excipient classes and ranges.
A conventional 1% silver sulfadiazine cream falls within the stated concentration range, but the complete claim 6 analysis requires the actual excipient composition.
The patent issued September 25, 1973, and expired approximately September 25, 1990.
It creates no current U.S. patent barrier, Paragraph IV risk, settlement leverage, or litigation stay.
Silver sulfadiazine is regulated as a small-molecule drug through the ANDA pathway, not as a biosimilar.
Current competitive barriers are primarily FDA compliance, manufacturing quality, supply, branding, and later formulation or device patents.

FAQs

Can a generic company sell 1% silver sulfadiazine cream without licensing Patent 3,761,590?

Yes. The patent expired in 1990, so a current manufacturer does not need a license under that patent.

Does claim 6 cover every silver sulfadiazine cream?

No. Claim 6 requires the formulation to meet specified ingredient classes and percentage ranges. A cream can contain 1% silver sulfadiazine yet fall outside claim 6 if its carrier or excipient profile differs.

Is silver sulfadiazine subject to biosimilar competition?

No. Silver sulfadiazine is a small-molecule active ingredient. Competition occurs through generic drug applications, not biosimilar applications.

Could a later patent still block a silver sulfadiazine product?

Yes. A later patent could potentially cover a particular formulation, delivery device, manufacturing process, combination, or indication. Such a patent would be separate from Patent 3,761,590.

Does the expired patent establish ownership of the silver sulfadiazine molecule?

No. The patent claims therapeutic use and formulations. It is not a current composition-of-matter monopoly over silver sulfadiazine.

References

United States Patent and Trademark Office. (1973). U.S. Patent No. 3,761,590, Treatment of burns with silver sulfadiazine.
U.S. Food and Drug Administration. (n.d.). Silvadene cream 1% prescribing information.
United States Code. (1994). 35 U.S.C. § 154: Contents and term of patents; provisional rights.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.

Details for Patent: 3,761,590

Summary for Patent: 3,761,590